These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 16632238

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
    Konya H, Hasegawa Y, Hamaguchi T, Satani K, Umehara A, Katsuno T, Ishikawa T, Miuchi M, Kohri K, Suehiro A, Kakishita E, Miyagawa J, Namba M.
    Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo antioxidant properties of gliclazide.
    O'Brien RC, Luo M, Balazs N, Mercuri J.
    J Diabetes Complications; 2000 Sep; 14(4):201-6. PubMed ID: 11004429
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes.
    Fava D, Cassone-Faldetta M, Laurenti O, De Luca O, Ghiselli A, De Mattia G.
    Diabet Med; 2002 Sep; 19(9):752-7. PubMed ID: 12207812
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Glibenclamide vs gliclazide in type 2 diabetes of the elderly.
    Tessier D, Dawson K, Tétrault JP, Bravo G, Meneilly GS.
    Diabet Med; 1994 Dec; 11(10):974-80. PubMed ID: 7895463
    [Abstract] [Full Text] [Related]

  • 19. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
    Kigawa Y, Oba K, Futami-Suda S, Norose J, Yasuoka H, Suzuki K, Ouchi M, Watanabe K, Suzuki T, Nakano H.
    Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999
    [Abstract] [Full Text] [Related]

  • 20. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.
    Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.